Vol. 5 No. 8 (2025)
Reimbursement Reviews

Daratumumab (Darzalex SC)

decorative image of the issue cover

Published August 21, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Daratumumab (Darzalex SC), 1,800 mg per 15 mL (120 mg/mL) single-dose vial solution for subcutaneous injection.
  • Indication: Daratumumab in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.